Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andes-1537 in advanced solid tumors
NCT02508441Phase 1Terminated
- Sponsor
- Andes Biotechnologies
- Start
- Dec 2015
- Primary completion
- Nov 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of andes-1537 in solid tumor, sponsored by Andes Biotechnologies. Primary endpoint: Incidence of dose-limiting toxicities at 4 weeks. Started Dec 2015; status: terminated.
02
Drugs
andes-1537
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02508441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508441.